1. Scrip

Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market

 
• By Emily Hayes

The third IL-17 inhibitor on the US market will have a $3,500/month list price. But in a crowded, safety-conscious space like psoriasis, it's unclear how low the discounted price will need to go and whether competitive pricing would be enough to sway prescribers.

Valeant Pharmaceuticals International Inc.'s IL-17 inhibitor Siliq (brodalumab) may be stuck with a suicidal ideation black box warning and shackled with restricted distribution, but at least the list price in the US is competitive at $3,500 per month for the treatment of psoriasis – the lowest among biologics in the crowded market, according to the company.

Valeant announced April 21 that its patient access and pricing committee set this price as a means of positioning the drug as an option with "outstanding efficacy while being the most affordable injectable biologic for patients with moderate-to-severe plaque psoriasis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.